A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance

Journal of Virology

Volumn 76, Issue 13, 2002, Pages 6836-6840

  Harrigan, P Richard ^a   Salim, Mahboob ^a   Stammers, David K ^a   Wynhoven, Brian ^a   Brumme, Zabrina L ^a   McKenna, Paula ^a   Larder, Brendan ^a   Kemp, S D ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AMINO ACID SUBSTITUTION; ARTICLE; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS RESISTANCE; 3' UNTRANSLATED REGION; ANTIBIOTIC RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MICROBIOLOGICAL EXAMINATION; MUTATION;

3' UNTRANSLATED REGIONS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035984019     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.13.6836-6840.2002     Document Type: Article

References (16)

1. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy
2. Nonnucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
3. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
4. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
5. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
6. Clinical uses of nonnucleoside reverse transcriptase inhibitors
7. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
8. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an IAS-USA panel
9. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent nonnucleoside inhibitors
10. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
11. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro
12. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
13. Mutational analysis of Tyr-318 within the nonnucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase
14. High resolution structures of HIV-1 RT from four RT-inhibitor complexes
15. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase
16. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1